cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Novo Nordisk's stock drops despite hitting goal of III trial Cagrilintide and cagrisema phase 3 results 2025

By week 24, total weight loss from baseline commonly falls in the 12-18% range, though individual results vary significantly based on starting weight, diet, exercise, and metabolic factors

Mild soreness or redness at the injection site can occur, but usually resolves quickly

Microscopically, the treated animals retained more axons and showed less white matter damage

The long-term safety of BPC-157 for human use is not established, as no controlled clinical trials have examined sustained administration beyond short-term animal study durations

Vascular issues Though rare, overuse of therapeutic B12 may lead to vascular events: Clots in deep veins Swelling in the legs Risk of pulmonary complications in sensitive groups Tabular View for Quick Recap You should report symptoms early to stop things from getting worse